María Ángeles
Solinís Aspiazu
Universidad del País Vasco/Euskal Herriko Unibertsitatea
Lejona, EspañaPublicacións en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (109)
2024
-
Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893
-
Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells
Journal of Drug Delivery Science and Technology, Vol. 99
-
Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach
Antibiotics, Vol. 13, Núm. 6
-
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
BioDrugs, Vol. 38, Núm. 5, pp. 657-680
-
Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review
Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628
2023
-
Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study
Blood Purification, Vol. 52, Núm. 5, pp. 464-473
-
Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
Pharmaceutics, Vol. 15, Núm. 7
-
Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
Pharmaceutics, Vol. 15, Núm. 4
-
siRNA vectors based on golden lipid nanoparticles for Fabry Disease
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
2022
-
Community Pharmacy and Primary Health Care - Types of integration
FIP World Congress of Pharmacy and Pharmaceutical Sciences (80º. Sevilla. 2022)
-
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
Nanomaterials, Vol. 12, Núm. 14
-
Oferta de servicios de atención farmacéutica: clave para un nuevo modelo de servicios de salud = Supply of pharmaceutical care services: The key to a new model of health services
Atención Primaria, Vol. 54, Núm. 1, pp. 102-198
-
Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study
Journal of Intensive Care, Vol. 10, Núm. 1
-
mRNA delivery technologies: Toward clinical translation
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293
2021
-
Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71
-
Farmazia-zerbitzu profesional asistentzialak Euskal Autonomia Erkidegoko (EAE) farmazietan
Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 39, pp. 131-152
-
Investigación sobre servicios profesionales farmacéuticos asistenciales en el marco de los trabajos fin de grado desarrollados durante las prácticas tuteladas
Congreso de la Sociedad Española de Farmacia Industrial y Galénica (SEFIG) (15º. Sevilla. 2021)
-
Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation
Pharmaceutics, Vol. 13, Núm. 9